Novo Nordisk is rated a Strong Buy as it shifts to a high-volume, lower-price model, improving operational efficiency and leveraging AI for cost savings. Recent FDA approvals for Wegovy HD and Awiqli, along with a strategic partnership with OpenAI, support ongoing innovation and supply chain independence. Despite challenges like patent expirations and price pressures, the company's valuation remains attractive with a P/E of 12.29 and a free cash flow yield near 4.7%. Upcoming catalysts include growth in US Wegovy volumes, oral Wegovy rollout, potential share buybacks, and new obesity therapy developments.
The US announced a phased tariff plan on imported generic drugs starting August 1, 2026, with zero tariffs for two years, followed by a 100% tariff in August 2028 and 200% in 2029. This move aims to encourage generic drugmakers to relocate production...
Novo Nordisk has filed a federal lawsuit against Eli Lilly, accusing the company of misleading advertising for its GLP-1 drugs Zepbound and Mounjaro. Novo claims Lilly's ads use outdated data and unfairly compare Lilly's highest drug doses to lower d...
Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of running misleading ads that inaccurately claim superior efficacy of Lilly's obesity and diabetes drugs compared to Novo's. The lawsuit targets ads that use outdated clinical ...
Novo Nordisk's shares have risen about 27% due to strong commercial growth of oral Wegovy, which holds 89% of new U.S. prescriptions compared to Eli Lilly's 11%. Over 80% of these prescriptions are from new GLP-1 patients, expanding the market rather...
Citi has increased its price target for Novo Nordisk to DKK330 ahead of the company's Q2 results, citing strong sales from the Wegovy pill launch. The broker raised its 2026 sales and operating income estimates by 4-5%, and earnings per share forecas...
